[go: up one dir, main page]

NI201800014A - Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h - Google Patents

Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Info

Publication number
NI201800014A
NI201800014A NI201800014A NI201800014A NI201800014A NI 201800014 A NI201800014 A NI 201800014A NI 201800014 A NI201800014 A NI 201800014A NI 201800014 A NI201800014 A NI 201800014A NI 201800014 A NI201800014 A NI 201800014A
Authority
NI
Nicaragua
Prior art keywords
inhibitor
isocitrate dehydrogenase
adduct
idh1
mutated isocitrate
Prior art date
Application number
NI201800014A
Other languages
English (en)
Inventor
Schirmer Heiko
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of NI201800014A publication Critical patent/NI201800014A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al ácido aductivo (2E)-but-2-endioico y ácido 3-)2-{[4-(trifluorometoxi)fenil]amino}-1-[(1R,5R)- 3,3,5 -trimetilciclohexil]-1H-benzimidazol-5-il)propanoico (1:4), a métodos para preparar este aducto, composiciones que comprenden este aducto y, también al uso de este aducto para preparar un medicamento para el tratamiento de una enfermedad.
NI201800014A 2015-07-27 2018-01-26 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h NI201800014A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15178419 2015-07-27

Publications (1)

Publication Number Publication Date
NI201800014A true NI201800014A (es) 2018-09-06

Family

ID=53758092

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201800014A NI201800014A (es) 2015-07-27 2018-01-26 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Country Status (26)

Country Link
US (1) US10344004B2 (es)
EP (1) EP3328837B1 (es)
JP (1) JP6804516B2 (es)
KR (1) KR20180030789A (es)
CN (1) CN107810181B (es)
AR (1) AR105493A1 (es)
AU (1) AU2016300980B2 (es)
BR (1) BR112018001534A2 (es)
CA (1) CA2993473A1 (es)
CL (1) CL2018000249A1 (es)
CO (1) CO2018000793A2 (es)
CR (1) CR20180053A (es)
CU (1) CU20180014A7 (es)
DO (1) DOP2018000027A (es)
EA (1) EA201890386A1 (es)
EC (1) ECSP18006465A (es)
ES (1) ES2860693T3 (es)
HK (1) HK1252449A1 (es)
IL (1) IL256024A (es)
MX (1) MX2018001205A (es)
NI (1) NI201800014A (es)
PE (1) PE20181038A1 (es)
SV (1) SV2018005621A (es)
TN (1) TN2018000038A1 (es)
TW (1) TW201708193A (es)
WO (1) WO2017016992A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015121210A1 (en) 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
CA2939021C (en) 2014-02-11 2022-07-12 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
WO2016062770A1 (en) 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
US10370339B2 (en) 2015-06-08 2019-08-06 Bayer Pharma Aktiengesellschaft N-Methylbenzimidazoles as mIDH1 inhibitors
CA2991360A1 (en) 2015-07-07 2017-01-12 Bayer Pharma Aktiengesellschaft 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
US10414734B2 (en) 2015-07-16 2019-09-17 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
WO2019015672A1 (zh) * 2017-07-21 2019-01-24 南京明德新药研发股份有限公司 吡啶并咪唑类化合物及其应用
EP3661559A1 (en) * 2017-08-01 2020-06-10 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Combination of midh1 inhibitors and dna hypomethylating agents (hma)
CN108948205B (zh) * 2018-07-13 2021-09-28 北京金岱生物科技有限公司 抗idh1r132h单克隆抗体及其应用
TWI760017B (zh) 2019-12-23 2022-04-01 大陸商昆藥集團股份有限公司 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法
WO2022019289A1 (ja) 2020-07-21 2022-01-27 第一三共株式会社 テモゾロミドと変異型ｉｄｈ１酵素阻害剤の組み合わせ医薬

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9125901B2 (en) 2009-06-23 2015-09-08 The Translational Genomics Research Institute 4-(benzimidazol-2-ylamino)benzamide derivatives and salts or solvates thereof
CN103476770B (zh) * 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
MX342326B (es) * 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
WO2015121210A1 (en) * 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
CA2939021C (en) 2014-02-11 2022-07-12 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
JP6783756B2 (ja) * 2014-10-23 2020-11-11 ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ ｍＩＤＨ１阻害剤としてのベンゾイミダゾール−２−アミン
WO2016062770A1 (en) 2014-10-23 2016-04-28 Bayer Pharma Aktiengesellschaft 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors
US10370339B2 (en) * 2015-06-08 2019-08-06 Bayer Pharma Aktiengesellschaft N-Methylbenzimidazoles as mIDH1 inhibitors
CA2991360A1 (en) 2015-07-07 2017-01-12 Bayer Pharma Aktiengesellschaft 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors
US10414734B2 (en) * 2015-07-16 2019-09-17 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) * 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法

Also Published As

Publication number Publication date
CA2993473A1 (en) 2017-02-02
KR20180030789A (ko) 2018-03-26
PE20181038A1 (es) 2018-07-03
AR105493A1 (es) 2017-10-11
MX2018001205A (es) 2018-04-24
CN107810181B (zh) 2021-06-22
TN2018000038A1 (en) 2019-07-08
CN107810181A (zh) 2018-03-16
EA201890386A1 (ru) 2018-08-31
EP3328837A1 (en) 2018-06-06
EP3328837B1 (en) 2021-01-06
CR20180053A (es) 2018-03-20
CO2018000793A2 (es) 2018-05-10
BR112018001534A2 (pt) 2018-09-11
DOP2018000027A (es) 2018-02-28
WO2017016992A1 (en) 2017-02-02
HK1252449A1 (zh) 2019-05-24
CU20180014A7 (es) 2018-06-05
AU2016300980B2 (en) 2020-12-24
IL256024A (en) 2018-01-31
US20180222870A1 (en) 2018-08-09
ECSP18006465A (es) 2018-04-30
AU2016300980A1 (en) 2017-12-21
TW201708193A (zh) 2017-03-01
CL2018000249A1 (es) 2018-07-06
US10344004B2 (en) 2019-07-09
JP6804516B2 (ja) 2020-12-23
SV2018005621A (es) 2018-12-05
ES2860693T3 (es) 2021-10-05
JP2018521095A (ja) 2018-08-02

Similar Documents

Publication Publication Date Title
NI201800014A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
CO2018006299A2 (es) Compuestos novedosos
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
EA201790398A1 (ru) Способы лечения заболевания печени
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
MX389802B (es) Composiciones enriquecidas estereoquimicamente para administracion de acidos nucleicos.
EA201790286A1 (ru) Способ получения кабозантиниба, меченного фтором-18, и его аналогов
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
DOP2016000253A (es) Nuevos compuestos
CO2018000795A2 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
AR102203A1 (es) Composiciones para el cuidado oral que comprenden zinc, arginina y serina
CR20140527A (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
EP4599830A3 (en) Isoxazoline compounds for use in treating demodicosis
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA201691498A1 (ru) Новая мишень для лечения и профилактики диабета
MX366651B (es) Forma a cristalina de (r)-2-((3-(3-aminopiperidin-1-il)-6-metil-5- oxo-1,2,4-triazin-4(5h)-il)metil)-4-fluorobenzonitrilo monobenzoato y método de preparación del mismo y composición farmacéutica que comprende la misma.
CR20160369A (es) Composiciones para uso en el tratamiento de afecciones alérgicas
MX375468B (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
MX2018006631A (es) Compuesto para uso en la prevencion y tratamiento de enfermedades neurodegenerativas.
CL2017000872A1 (es) Composiciones y métodos para la inhibición de la expresión génica de hao1 (hidroxiácido oxidasa 1 (glicolato oxidasa)